Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study
A rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was prevailing since July 2021. We aimed to determine whether the risk of a severe hospital event following symptomatic SARS-CoV-2 infection differs for Omi...
Saved in:
Published in | EClinicalMedicine Vol. 48; p. 101455 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.06.2022
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | A rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was prevailing since July 2021. We aimed to determine whether the risk of a severe hospital event following symptomatic SARS-CoV-2 infection differs for Omicron versus Delta.
We conducted a retrospective cohort study to compare severe hospital events (admission to intensive care unit or death) between Omicron and Delta symptomatic cases matched according to week of virological diagnosis and age. The analysis was adjusted for age, sex, vaccination status, presence of comorbidities and region of residence, using Cox proportional hazards model.
Between 06/12/2021–28/01/2022, 184 364 cases were included, of which 931 had a severe hospital event (822 Delta, 109 Omicron). The risk of severe event was lower among Omicron versus Delta cases; the difference in severity between the two variants decreased with age (adjusted Hazard Ratio (aHR)=0·13 95%CI: 0·08–0·20 among 40–64 years, aHR=0·50 95%CI: 0·26–0.98 among 80+ years). The risk of severe event increased with the presence of comorbidities (for very-high-risk comorbidity, aHR=4·15 95%CI: 2·86–6·01 among 40–64 years) and in males (aHR=2·28 95%CI: 1·82–2·85among 40–64 years) and was higher in unvaccinated compared to primo-vaccinated (aHR=7·29 95%CI: 5·58–9·54 among 40–64 years). A booster dose reduced the risk of severe hospital event in 80+ years infected with Omicron (aHR=0·29; 95%CI: 0·12–0·69).
This study confirms the lower severity of Omicron compared to Delta. However, the difference in disease severity is less marked in the elderly. Further studies are needed to better understand the interactions between age and severity of variants.
The study was performed as part of routine work at Public Health France. |
---|---|
AbstractList | BackgroundA rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was prevailing since July 2021. We aimed to determine whether the risk of a severe hospital event following symptomatic SARS-CoV-2 infection differs for Omicron versus Delta. MethodsWe conducted a retrospective cohort study to compare severe hospital events (admission to intensive care unit or death) between Omicron and Delta symptomatic cases matched according to week of virological diagnosis and age. The analysis was adjusted for age, sex, vaccination status, presence of comorbidities and region of residence, using Cox proportional hazards model. FindingsBetween 06/12/2021-28/01/2022, 184 364 cases were included, of which 931 had a severe hospital event (822 Delta, 109 Omicron). The risk of severe event was lower among Omicron versus Delta cases; the difference in severity between the two variants decreased with age (adjusted Hazard Ratio (aHR)=0·13 95%CI: 0·08-0·20 among 40-64 years, aHR=0·50 95%CI: 0·26-0.98 among 80+ years). The risk of severe event increased with the presence of comorbidities (for very-high-risk comorbidity, aHR=4·15 95%CI: 2·86-6·01 among 40-64 years) and in males (aHR=2·28 95%CI: 1·82-2·85among 40-64 years) and was higher in unvaccinated compared to primo-vaccinated (aHR=7·29 95%CI: 5·58-9·54 among 40-64 years). A booster dose reduced the risk of severe hospital event in 80+ years infected with Omicron (aHR=0·29; 95%CI: 0·12-0·69). InterpretationThis study confirms the lower severity of Omicron compared to Delta. However, the difference in disease severity is less marked in the elderly. Further studies are needed to better understand the interactions between age and severity of variants. FundingThe study was performed as part of routine work at Public Health France. Background: A rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was prevailing since July 2021. We aimed to determine whether the risk of a severe hospital event following symptomatic SARS-CoV-2 infection differs for Omicron versus Delta. Methods: We conducted a retrospective cohort study to compare severe hospital events (admission to intensive care unit or death) between Omicron and Delta symptomatic cases matched according to week of virological diagnosis and age. The analysis was adjusted for age, sex, vaccination status, presence of comorbidities and region of residence, using Cox proportional hazards model. Findings: Between 06/12/2021–28/01/2022, 184 364 cases were included, of which 931 had a severe hospital event (822 Delta, 109 Omicron). The risk of severe event was lower among Omicron versus Delta cases; the difference in severity between the two variants decreased with age (adjusted Hazard Ratio (aHR)=0·13 95%CI: 0·08–0·20 among 40–64 years, aHR=0·50 95%CI: 0·26–0.98 among 80+ years). The risk of severe event increased with the presence of comorbidities (for very-high-risk comorbidity, aHR=4·15 95%CI: 2·86–6·01 among 40–64 years) and in males (aHR=2·28 95%CI: 1·82–2·85among 40–64 years) and was higher in unvaccinated compared to primo-vaccinated (aHR=7·29 95%CI: 5·58–9·54 among 40–64 years). A booster dose reduced the risk of severe hospital event in 80+ years infected with Omicron (aHR=0·29; 95%CI: 0·12–0·69). Interpretation: This study confirms the lower severity of Omicron compared to Delta. However, the difference in disease severity is less marked in the elderly. Further studies are needed to better understand the interactions between age and severity of variants. Funding: The study was performed as part of routine work at Public Health France. A rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was prevailing since July 2021. We aimed to determine whether the risk of a severe hospital event following symptomatic SARS-CoV-2 infection differs for Omicron versus Delta. We conducted a retrospective cohort study to compare severe hospital events (admission to intensive care unit or death) between Omicron and Delta symptomatic cases matched according to week of virological diagnosis and age. The analysis was adjusted for age, sex, vaccination status, presence of comorbidities and region of residence, using Cox proportional hazards model. Between 06/12/2021-28/01/2022, 184 364 cases were included, of which 931 had a severe hospital event (822 Delta, 109 Omicron). The risk of severe event was lower among Omicron versus Delta cases; the difference in severity between the two variants decreased with age (adjusted Hazard Ratio (aHR)=0·13 95%CI: 0·08-0·20 among 40-64 years, aHR=0·50 95%CI: 0·26-0.98 among 80+ years). The risk of severe event increased with the presence of comorbidities (for very-high-risk comorbidity, aHR=4·15 95%CI: 2·86-6·01 among 40-64 years) and in males (aHR=2·28 95%CI: 1·82-2·85among 40-64 years) and was higher in unvaccinated compared to primo-vaccinated (aHR=7·29 95%CI: 5·58-9·54 among 40-64 years). A booster dose reduced the risk of severe hospital event in 80+ years infected with Omicron (aHR=0·29; 95%CI: 0·12-0·69). This study confirms the lower severity of Omicron compared to Delta. However, the difference in disease severity is less marked in the elderly. Further studies are needed to better understand the interactions between age and severity of variants. The study was performed as part of routine work at Public Health France. |
ArticleNumber | 101455 |
Author | Schaeffer, Justine Tamandjou, Cynthia Strat, Yann Le Auvigne, Vincent Levy-Bruhl, Daniel Fournier, Lucie Montagnat, Charline Coignard, Bruno Vaux, Sophie Parent du Châtelet, Isabelle |
Author_xml | – sequence: 1 givenname: Vincent orcidid: 0000-0003-3960-3987 surname: Auvigne fullname: Auvigne, Vincent email: vincent.auvigne@santepubliquefrance.fr organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France – sequence: 2 givenname: Sophie surname: Vaux fullname: Vaux, Sophie organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France – sequence: 3 givenname: Yann Le surname: Strat fullname: Strat, Yann Le organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France – sequence: 4 givenname: Justine orcidid: 0000-0003-4311-3294 surname: Schaeffer fullname: Schaeffer, Justine organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France – sequence: 5 givenname: Lucie surname: Fournier fullname: Fournier, Lucie organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France – sequence: 6 givenname: Cynthia surname: Tamandjou fullname: Tamandjou, Cynthia organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France – sequence: 7 givenname: Charline surname: Montagnat fullname: Montagnat, Charline organization: Sully Group, 3 av. Doyen Louis Weil, Grenoble 38000 France – sequence: 8 givenname: Bruno surname: Coignard fullname: Coignard, Bruno organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France – sequence: 9 givenname: Daniel surname: Levy-Bruhl fullname: Levy-Bruhl, Daniel organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France – sequence: 10 givenname: Isabelle surname: Parent du Châtelet fullname: Parent du Châtelet, Isabelle organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35611065$$D View this record in MEDLINE/PubMed |
BookMark | eNp9Uk1u1DAUjlARLaU3QMhLFs1gO7GTsECqphSKKnXRiq3l2C8zHiV2sJ2pZscduBFH4SQ4TCntho3t9_d9n997L7MD6yxk2WuCFwQT_m6zANUbOywopnR2lYw9y44oq5ucFRU-ePQ-zE5C2GCMKS7rhuMX2WHBOCGYs6Ps5w1swQNauzCaKHuUTBsD6lzfuztjVyjshjG6QUajkLEdqGicRXcmrtGN9CFfuq85RdeDUT75pdXoHPoo0VZ6I2coY9GFl1bBaYooGFrwKMkmv77_-CLtJP1uNul7dIY8RJ-EzBzblD66cerlzJe3MoA-RUmGWoNGyq2djyjESe9eZc872Qc4ub-Ps9uLj7fLz_nV9afL5dlVrkrWxFx3XV3KlqgOF0wDZ7pQUOKq0bjShHDd1rSCVtW6KYFhxbua6XSQGresK4rj7HIPq53ciNGbISkXThrxx-H8SkifmtSD4LRihWa10rQrS87bMnmKQkrNcFEQnrA-7LHGqR1Aq9RyL_snoE8j1qzFym1FQyhpcJUA3t4DePdtghDFYIKCvpcW3BQE5bxJXDWfucp9appPCB66BxqCxbxMYiP2yyTmMYj9MqWyN48lPhT9XZ1_f4DU860BL4IykMasjU8DTF0x_2f4DaSS4ks |
CitedBy_id | crossref_primary_10_1093_cid_ciad287 crossref_primary_10_3390_ijerph20042987 crossref_primary_10_3390_vaccines10111885 crossref_primary_10_2174_0118715265279242240216114548 crossref_primary_10_1016_j_jiph_2023_05_004 crossref_primary_10_3389_fpubh_2023_1218188 crossref_primary_10_3390_ijerph20042779 crossref_primary_10_1186_s12985_023_02014_1 crossref_primary_10_1017_S0950268823001358 crossref_primary_10_3390_vaccines11121803 crossref_primary_10_1001_jamanetworkopen_2022_27241 crossref_primary_10_3390_jcm12062371 crossref_primary_10_1016_j_jtcme_2024_05_004 crossref_primary_10_3390_microbiolres14020057 crossref_primary_10_1186_s12879_023_08257_1 crossref_primary_10_3389_fimmu_2023_1130539 crossref_primary_10_1001_jamanetworkopen_2023_54991 crossref_primary_10_1016_j_tifs_2022_12_012 crossref_primary_10_1080_21645515_2023_2167410 crossref_primary_10_1186_s12879_023_08714_x crossref_primary_10_1136_bmjgh_2023_012328 crossref_primary_10_1016_j_cmi_2022_12_020 crossref_primary_10_1093_eurjpc_zwac228 crossref_primary_10_1371_journal_pgph_0001896 crossref_primary_10_3389_fmicb_2023_1051104 crossref_primary_10_1007_s11845_022_03266_6 crossref_primary_10_1093_ofid_ofac406 crossref_primary_10_1038_s41598_023_48272_5 crossref_primary_10_1080_21645515_2023_2212568 crossref_primary_10_1016_j_vaccine_2023_02_062 crossref_primary_10_1177_14034948221108548 crossref_primary_10_1097_MD_0000000000033024 crossref_primary_10_1038_s41598_023_41060_1 crossref_primary_10_1093_cid_ciac933 crossref_primary_10_1136_bmjopen_2023_076892 |
Cites_doi | 10.1186/s13293-020-00304-9 10.1016/j.ijid.2021.12.357 10.1038/s41586-022-04465-y 10.1016/S0140-6736(22)00462-7 10.1038/s41586-022-04441-6 10.1056/NEJMc2200133 10.3389/fpubh.2020.00152 10.1038/d41586-021-03552-w 10.1001/jama.2021.24868 10.1038/nri2318 10.2139/ssrn.3996320 10.2807/1560-7917.ES.2022.27.4.2200077 10.1056/NEJMc2119270 10.2807/1560-7917.ES.2022.27.13.2200247 10.15585/mmwr.mm6924e2 10.1126/sciimmunol.abo2202 10.1038/s41586-022-04460-3 10.1038/s41586-022-04479-6 |
ContentType | Journal Article |
Copyright | 2022 The Author(s) 2022 The Author(s). 2022 The Author(s) 2022 |
Copyright_xml | – notice: 2022 The Author(s) – notice: 2022 The Author(s). – notice: 2022 The Author(s) 2022 |
DBID | 6I. AAFTH NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.1016/j.eclinm.2022.101455 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2589-5370 |
EndPage | 101455 |
ExternalDocumentID | oai_doaj_org_article_62753d58cd2f4466b462733aad503316 10_1016_j_eclinm_2022_101455 35611065 S2589537022001857 |
Genre | Journal Article |
GroupedDBID | .1- .FO 0SF 53G 6I. AACTN AAEDW AAFTH AALRI AAXUO ABMAC ACLIJ ADBBV AEXQZ AFCTW AFRHN AFTJW AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS BCNDV EBS EJD FDB GROUPED_DOAJ HYE M41 NCXOZ OK1 ROL RPM SSZ Z5R 0R~ AAMRU ADVLN NPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c459t-dff84ab1cf035de65d3ce4079d07d116db827ebc8d94e50c6f85d6f8180b5f33 |
IEDL.DBID | RPM |
ISSN | 2589-5370 |
IngestDate | Tue Oct 22 15:12:32 EDT 2024 Tue Sep 17 21:14:54 EDT 2024 Wed Jul 24 17:12:30 EDT 2024 Thu Sep 26 19:36:25 EDT 2024 Sat Sep 28 08:19:14 EDT 2024 Tue Jul 25 20:59:41 EDT 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | COVID-19 SARS-CoV-2 Omicron Delta Epidemiology Vaccination |
Language | English |
License | This is an open access article under the CC BY-NC-ND license. 2022 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c459t-dff84ab1cf035de65d3ce4079d07d116db827ebc8d94e50c6f85d6f8180b5f33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-4311-3294 0000-0003-3960-3987 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121907/ |
PMID | 35611065 |
PQID | 2669503866 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_62753d58cd2f4466b462733aad503316 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9121907 proquest_miscellaneous_2669503866 crossref_primary_10_1016_j_eclinm_2022_101455 pubmed_primary_35611065 elsevier_sciencedirect_doi_10_1016_j_eclinm_2022_101455 |
PublicationCentury | 2000 |
PublicationDate | 2022-06-01 |
PublicationDateYYYYMMDD | 2022-06-01 |
PublicationDate_xml | – month: 06 year: 2022 text: 2022-06-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | EClinicalMedicine |
PublicationTitleAlternate | EClinicalMedicine |
PublicationYear | 2022 |
Publisher | Elsevier Ltd Elsevier |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
References | Keeton, Tincho, Ngomti (bib0022) 2022; 603 Sante publique France. Risk analysis on emerging variants of SARS-CoV-2 carried out jointly by Public Health France and the CNR for respiratory infection viruses update of 05/01/2022. 2022 Jassat, Karim, Mudara (bib0007) 2021 Veneti, Bøås, Bråthen Kristoffersen (bib0017) 2022; 27 Nikolich-Zugich (bib0027) 2008; 8 Bastard, Taisne, Figoni (bib0031) 2022; 27 Ministère des solidarités et de la Santé. Le Gouvernement ouvre la vaccination aux patients vulnérables à très haut risque à compter du 18 janvier - Ministère des Solidarités et de la Santé (solidarites-sante.gouv.fr). 2022 Bentley, Kirby, Sharma, Kipar, Mega, Bramwell (bib0023) 2021 Sante publique France. COVID-19: epidemiological update. Weekly report. Week 1. 13 January 2022. 2022 Altarawneh, Chemaitelly, Hasan (bib0032) 2022; 386 Jin, Bai, He (bib0030) 2020; 8 Callaway (bib0001) 2021; 600 Lu, Mok, Chen (bib0018) 2021 Lefrancq, Paireau, Hoze (bib0012) 2021; 5 Wolter, Jassat, Walaza, Welch, Moultrie, Groome (bib0013) 2021 Abdullah, Myers, Basu (bib0006) 2021; 116 Nyberg, Ferguson, Nash (bib0016) 2022; 399 Maslo, Friedland, Toubkin, Laubscher, Akaloo, Kama (bib0008) 2021; 327 Stokes, Zambrano, Anderson (bib0028) 2020; 69 Davies, Kassanjee, Rousseau, Morden, Johnson, Solomon (bib0009) 2022; Online ahead of print Liu, Chandrashekar, Sellers, Barrett, Jacob-Dolan, Lifton (bib0021) 2022; 603 Lewnard, Hong, Patel, Kahn, Lipsitch, Tartof (bib0015) 2022 Madhi, Kwatra, Myers, Jassat, Dhar, Mukendi (bib0005) 2022 . Hui, Ho, Cheung (bib0025) 2022; 603 Gebhard, Regitz-Zagrosek, Neuhauser, Morgan, Klein (bib0029) 2020; 11 Ulloa, Buchan, Daneman, Brown (bib0014) 2022 Accessed 5 May 2022. Accessed 5 May 2022 Collie, Champion, Moultrie, Bekker, Gray (bib0019) 2021; 386 GeurtsvanKessel, Geers, Schmitz (bib0020) 2022; 7 (bib0002) 2022 Halfmann, Iida, Iwatsuki-Horimoto, Maemura, Kiso, Scheaffer (bib0024) 2022; 603 Jassat (10.1016/j.eclinm.2022.101455_bib0007) 2021 Lefrancq (10.1016/j.eclinm.2022.101455_bib0012) 2021; 5 Collie (10.1016/j.eclinm.2022.101455_bib0019) 2021; 386 10.1016/j.eclinm.2022.101455_bib0003 Hui (10.1016/j.eclinm.2022.101455_bib0025) 2022; 603 Bentley (10.1016/j.eclinm.2022.101455_bib0023) 2021 GeurtsvanKessel (10.1016/j.eclinm.2022.101455_bib0020) 2022; 7 10.1016/j.eclinm.2022.101455_bib0004 Ulloa (10.1016/j.eclinm.2022.101455_bib0014) 2022 Nyberg (10.1016/j.eclinm.2022.101455_bib0016) 2022; 399 Bastard (10.1016/j.eclinm.2022.101455_bib0031) 2022; 27 Maslo (10.1016/j.eclinm.2022.101455_bib0008) 2021; 327 Jin (10.1016/j.eclinm.2022.101455_bib0030) 2020; 8 Wolter (10.1016/j.eclinm.2022.101455_bib0013) 2021 Liu (10.1016/j.eclinm.2022.101455_bib0021) 2022; 603 Nikolich-Zugich (10.1016/j.eclinm.2022.101455_bib0027) 2008; 8 Halfmann (10.1016/j.eclinm.2022.101455_bib0024) 2022; 603 Callaway (10.1016/j.eclinm.2022.101455_bib0001) 2021; 600 Abdullah (10.1016/j.eclinm.2022.101455_bib0006) 2021; 116 Davies (10.1016/j.eclinm.2022.101455_bib0009) 2022; Online ahead of print 10.1016/j.eclinm.2022.101455_bib0010 Lewnard (10.1016/j.eclinm.2022.101455_bib0015) 2022 Lu (10.1016/j.eclinm.2022.101455_bib0018) 2021 Madhi (10.1016/j.eclinm.2022.101455_bib0005) 2022 Keeton (10.1016/j.eclinm.2022.101455_bib0022) 2022; 603 Altarawneh (10.1016/j.eclinm.2022.101455_bib0032) 2022; 386 Gebhard (10.1016/j.eclinm.2022.101455_bib0029) 2020; 11 Veneti (10.1016/j.eclinm.2022.101455_bib0017) 2022; 27 Stokes (10.1016/j.eclinm.2022.101455_bib0028) 2020; 69 (10.1016/j.eclinm.2022.101455_bib0002) 2022 |
References_xml | – volume: 600 start-page: 21 year: 2021 ident: bib0001 article-title: Heavily mutated Omicron variant puts scientists on alert publication-title: Nature contributor: fullname: Callaway – volume: 69 start-page: 759 year: 2020 end-page: 765 ident: bib0028 article-title: Coronavirus disease 2019 case surveillance-United States, January 22–May 30, 2020 publication-title: MMWR Morb Mortal Wkly Rep contributor: fullname: Anderson – volume: 116 start-page: 38 year: 2021 end-page: 42 ident: bib0006 article-title: Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa publication-title: Int J Infect Dis contributor: fullname: Basu – volume: 8 start-page: 152 year: 2020 ident: bib0030 article-title: Gender differences in patients with COVID-19: focus on severity and mortality publication-title: Front Public Health contributor: fullname: He – volume: 327 start-page: 583 year: 2021 end-page: 584 ident: bib0008 article-title: Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves publication-title: JAMA contributor: fullname: Kama – volume: 27 year: 2022 ident: bib0017 article-title: Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022 publication-title: Eurosurveillance contributor: fullname: Bråthen Kristoffersen – year: 2022 ident: bib0005 article-title: South African Population Immunity and Severe Covid-19 with Omicron Variant publication-title: medRxiv [preprint] contributor: fullname: Mukendi – year: 2021 ident: bib0007 article-title: Clinical severity of COVID-19 patients admitted to hospitals in Gauteng, South Africa during the Omicrondominant fourth wave publication-title: SSRN [preprint] contributor: fullname: Mudara – volume: 399 start-page: 1303 year: 2022 end-page: 1312 ident: bib0016 article-title: Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study publication-title: Lancet contributor: fullname: Nash – volume: 8 start-page: 512 year: 2008 end-page: 522 ident: bib0027 article-title: Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections publication-title: Nat Rev Immunol contributor: fullname: Nikolich-Zugich – volume: 5 year: 2021 ident: bib0012 article-title: Evolution of outcomes for patients hospitalised during the first 9 months of the SARS-CoV-2 pandemic in France: a retrospective national surveillance data analysis publication-title: Lancet Reg Health Eur contributor: fullname: Hoze – volume: 7 start-page: eabo2202 year: 2022 ident: bib0020 article-title: Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients publication-title: Sci Immunol contributor: fullname: Schmitz – year: 2021 ident: bib0023 article-title: SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19 publication-title: BioRxiv [preprint] contributor: fullname: Bramwell – year: 2022 ident: bib0015 article-title: Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California publication-title: medRxiv [preprint] contributor: fullname: Tartof – volume: 603 start-page: 493 year: 2022 end-page: 496 ident: bib0021 article-title: Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron publication-title: Nature contributor: fullname: Lifton – volume: 603 start-page: 488 year: 2022 end-page: 492 ident: bib0022 article-title: T cell responses to SARS-CoV-2 spike cross-recognize Omicron publication-title: Nature contributor: fullname: Ngomti – volume: 603 start-page: 687 year: 2022 end-page: 692 ident: bib0024 article-title: SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters publication-title: Nature contributor: fullname: Scheaffer – volume: Online ahead of print year: 2022 ident: bib0009 article-title: Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa publication-title: Tropical Medicine & International Health contributor: fullname: Solomon – year: 2022 ident: bib0002 article-title: Weekly epidemiological update on COVID-19 - 25 January 2022. Edition 76 – year: 2021 ident: bib0018 article-title: Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients publication-title: Clin Infect Dis contributor: fullname: Chen – year: 2022 ident: bib0014 article-title: Early estimates of SARS-CoV-2 Omicron variant severity based on a matched cohort study, Ontario, Canada publication-title: medRxiv [preprint] contributor: fullname: Brown – volume: 603 start-page: 715 year: 2022 end-page: 720 ident: bib0025 article-title: SARS-CoV-2 Omicron variant replication in human bronchus and lung publication-title: Nature contributor: fullname: Cheung – year: 2021 ident: bib0013 article-title: Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa publication-title: medRXiv [preprint] contributor: fullname: Groome – volume: 386 start-page: 1288 year: 2022 end-page: 1290 ident: bib0032 article-title: Protection against the Omicron variant from previous SARS-CoV-2 infection publication-title: N Engl J Med contributor: fullname: Hasan – volume: 11 start-page: 29 year: 2020 ident: bib0029 article-title: Impact of sex and gender on COVID-19 outcomes in Europe publication-title: Biol Sex Differ contributor: fullname: Klein – volume: 27 year: 2022 ident: bib0031 article-title: Impact of the Omicron variant on SARS-CoV-2 reinfections in France, March 2021 to February 2022 publication-title: Eurosurveillance contributor: fullname: Figoni – volume: 386 start-page: 494 year: 2021 end-page: 496 ident: bib0019 article-title: Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa publication-title: N Engl J Med contributor: fullname: Gray – volume: 11 start-page: 29 issue: 1 year: 2020 ident: 10.1016/j.eclinm.2022.101455_bib0029 article-title: Impact of sex and gender on COVID-19 outcomes in Europe publication-title: Biol Sex Differ doi: 10.1186/s13293-020-00304-9 contributor: fullname: Gebhard – volume: 116 start-page: 38 year: 2021 ident: 10.1016/j.eclinm.2022.101455_bib0006 article-title: Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2021.12.357 contributor: fullname: Abdullah – volume: 603 start-page: 493 year: 2022 ident: 10.1016/j.eclinm.2022.101455_bib0021 article-title: Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron publication-title: Nature doi: 10.1038/s41586-022-04465-y contributor: fullname: Liu – volume: 399 start-page: 1303 issue: 10332 year: 2022 ident: 10.1016/j.eclinm.2022.101455_bib0016 article-title: Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study publication-title: Lancet doi: 10.1016/S0140-6736(22)00462-7 contributor: fullname: Nyberg – year: 2022 ident: 10.1016/j.eclinm.2022.101455_bib0015 article-title: Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California publication-title: medRxiv [preprint] contributor: fullname: Lewnard – volume: 603 start-page: 687 year: 2022 ident: 10.1016/j.eclinm.2022.101455_bib0024 article-title: SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters publication-title: Nature doi: 10.1038/s41586-022-04441-6 contributor: fullname: Halfmann – volume: 386 start-page: 1288 issue: 13 year: 2022 ident: 10.1016/j.eclinm.2022.101455_bib0032 article-title: Protection against the Omicron variant from previous SARS-CoV-2 infection publication-title: N Engl J Med doi: 10.1056/NEJMc2200133 contributor: fullname: Altarawneh – volume: 8 start-page: 152 year: 2020 ident: 10.1016/j.eclinm.2022.101455_bib0030 article-title: Gender differences in patients with COVID-19: focus on severity and mortality publication-title: Front Public Health doi: 10.3389/fpubh.2020.00152 contributor: fullname: Jin – ident: 10.1016/j.eclinm.2022.101455_bib0003 – volume: 600 start-page: 21 issue: 7887 year: 2021 ident: 10.1016/j.eclinm.2022.101455_bib0001 article-title: Heavily mutated Omicron variant puts scientists on alert publication-title: Nature doi: 10.1038/d41586-021-03552-w contributor: fullname: Callaway – volume: 327 start-page: 583 year: 2021 ident: 10.1016/j.eclinm.2022.101455_bib0008 article-title: Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves publication-title: JAMA doi: 10.1001/jama.2021.24868 contributor: fullname: Maslo – year: 2021 ident: 10.1016/j.eclinm.2022.101455_bib0013 article-title: Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa publication-title: medRXiv [preprint] contributor: fullname: Wolter – year: 2022 ident: 10.1016/j.eclinm.2022.101455_bib0014 article-title: Early estimates of SARS-CoV-2 Omicron variant severity based on a matched cohort study, Ontario, Canada publication-title: medRxiv [preprint] contributor: fullname: Ulloa – volume: 8 start-page: 512 issue: 7 year: 2008 ident: 10.1016/j.eclinm.2022.101455_bib0027 article-title: Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections publication-title: Nat Rev Immunol doi: 10.1038/nri2318 contributor: fullname: Nikolich-Zugich – volume: 5 year: 2021 ident: 10.1016/j.eclinm.2022.101455_bib0012 article-title: Evolution of outcomes for patients hospitalised during the first 9 months of the SARS-CoV-2 pandemic in France: a retrospective national surveillance data analysis publication-title: Lancet Reg Health Eur contributor: fullname: Lefrancq – year: 2021 ident: 10.1016/j.eclinm.2022.101455_bib0007 article-title: Clinical severity of COVID-19 patients admitted to hospitals in Gauteng, South Africa during the Omicrondominant fourth wave publication-title: SSRN [preprint] doi: 10.2139/ssrn.3996320 contributor: fullname: Jassat – volume: Online ahead of print year: 2022 ident: 10.1016/j.eclinm.2022.101455_bib0009 article-title: Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa publication-title: Tropical Medicine & International Health contributor: fullname: Davies – year: 2022 ident: 10.1016/j.eclinm.2022.101455_bib0002 – ident: 10.1016/j.eclinm.2022.101455_bib0004 – volume: 27 issue: 4 year: 2022 ident: 10.1016/j.eclinm.2022.101455_bib0017 article-title: Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022 publication-title: Eurosurveillance doi: 10.2807/1560-7917.ES.2022.27.4.2200077 contributor: fullname: Veneti – year: 2021 ident: 10.1016/j.eclinm.2022.101455_bib0018 article-title: Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients publication-title: Clin Infect Dis contributor: fullname: Lu – volume: 386 start-page: 494 year: 2021 ident: 10.1016/j.eclinm.2022.101455_bib0019 article-title: Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa publication-title: N Engl J Med doi: 10.1056/NEJMc2119270 contributor: fullname: Collie – year: 2022 ident: 10.1016/j.eclinm.2022.101455_bib0005 article-title: South African Population Immunity and Severe Covid-19 with Omicron Variant publication-title: medRxiv [preprint] contributor: fullname: Madhi – volume: 27 issue: 13 year: 2022 ident: 10.1016/j.eclinm.2022.101455_bib0031 article-title: Impact of the Omicron variant on SARS-CoV-2 reinfections in France, March 2021 to February 2022 publication-title: Eurosurveillance doi: 10.2807/1560-7917.ES.2022.27.13.2200247 contributor: fullname: Bastard – volume: 69 start-page: 759 issue: 24 year: 2020 ident: 10.1016/j.eclinm.2022.101455_bib0028 article-title: Coronavirus disease 2019 case surveillance-United States, January 22–May 30, 2020 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm6924e2 contributor: fullname: Stokes – volume: 7 start-page: eabo2202 issue: 69 year: 2022 ident: 10.1016/j.eclinm.2022.101455_bib0020 article-title: Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients publication-title: Sci Immunol doi: 10.1126/sciimmunol.abo2202 contributor: fullname: GeurtsvanKessel – year: 2021 ident: 10.1016/j.eclinm.2022.101455_bib0023 article-title: SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19 publication-title: BioRxiv [preprint] contributor: fullname: Bentley – ident: 10.1016/j.eclinm.2022.101455_bib0010 – volume: 603 start-page: 488 year: 2022 ident: 10.1016/j.eclinm.2022.101455_bib0022 article-title: T cell responses to SARS-CoV-2 spike cross-recognize Omicron publication-title: Nature doi: 10.1038/s41586-022-04460-3 contributor: fullname: Keeton – volume: 603 start-page: 715 year: 2022 ident: 10.1016/j.eclinm.2022.101455_bib0025 article-title: SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo publication-title: Nature doi: 10.1038/s41586-022-04479-6 contributor: fullname: Hui |
SSID | ssj0002048960 |
Score | 2.4073918 |
Snippet | A rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was prevailing... BackgroundA rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was... Background: A rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was... |
SourceID | doaj pubmedcentral proquest crossref pubmed elsevier |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 101455 |
SubjectTerms | COVID-19 Delta Epidemiology Omicron SARS-CoV-2 Vaccination |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9RADB6hHhAXxJvlJSNx3IEkM5NMuJVCVVUqHFpQb1EyD7UVTVa7aave-A_8I34KvwR7Jllt4NALl5XyHq-_rO21_ZmxN86XRZKbhBNVCJeNzbk2heL4i9joss51E3gLDj7ne1_l_rE63hj1RTVhkR44fnHviEVXWKWNzTzlHhuJe4Soa0sJuDSSbadqI5g6C-k1qcvQIpwpXdJCkrFvLhR3Oeo7pEb0LHsbptWqiV0K9P0T8_Sv-_l3FeWGWdq9x-4O_iRsRznus1uufcBuHwwZ84fs16FDsDo4GeaDQGBsWoFH_XdXaLdgdX2-6LvA3ApjaVYL9P8sHGLUy3e6bzyDL-dUuddC3Vr46L73NVxilE1FNHgRhPEcbo5HjKMJI4Aip79__NyvW4TgNW1m72Eblq5fdmNz5xwW6-lhnKypnQMuA1Fkgeb2LnsI5LeP2NHup6OdPT7MbeBGqrLn1nst6yY1PhHKulxZYRwGjqVNCpumuW10VrjGaFtKpxKTe60sfqQ6aZQX4jHbarvWPWWgSyOkyrxwhZQuFbq2Aj0k6RIvNXpyM8ZHpVWLyM5RjWVrZ1VUckUiVlHJM_aBNLs-l7i1ww5EXDUgrroJcTNWjLioBjcluh94q9MbHv96hFGFbzGlZurWdRerCt2kkoh5crz7kwir9SIFurgYuOPVxQRwEymmR9rTk8AUXqZokJLi2f8Q-zm7Q6LEMrkXbKtfXriX6JD1zavw7v0BVnMy_w priority: 102 providerName: Directory of Open Access Journals |
Title | Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study |
URI | https://dx.doi.org/10.1016/j.eclinm.2022.101455 https://www.ncbi.nlm.nih.gov/pubmed/35611065 https://search.proquest.com/docview/2669503866 https://pubmed.ncbi.nlm.nih.gov/PMC9121907 https://doaj.org/article/62753d58cd2f4466b462733aad503316 |
Volume | 48 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtNAEF61PSAuiH_CTzVIHLOJ7d2119xKoKoqBZBaUG-WvT80VWNHjgvqjXfgjXgUnoTZtTdq4IDEJVLs2N7VzGRmPN98Q8grY_MsSlVEHVUI5ZVOqVSZoPiPWMm8TGXleQvm79OjT_z4TJztEBF6YTxoX1WLSX25nNSLc4-tXC3VNODEph_nszxGO4uy6S7ZzRi7kaJf-MoalxiWhzY5j-Uyrs3Q9Z0nycQPp3UDaxiGDpgQiS2P5In7txzT34Hnn_jJGw7p8C65M0SScNCv-B7ZMfV9cms-1MofkJ8nBtXUwPkwGQQ8V9MaLEq--YYeC9bXy1XXeM5WCKCsGtybWTjBfJfOms80gQ9Lh9mroaw1vDWXXQlfMb928Bm8CPxgDjPGM8q42SKAu49_ff9xXNaofNfua_IaDqA1XduEts4xrDZzw6jzo3oMuAzUHw1uYm_bgae9fUhOD9-dzo7oMLGBKi7yjmprJS-rWNmICW1SoZkymDLmOsp0HKe6kklmKiV1zo2IVGql0PgRy6gSlrFHZK9uavOEgMwV4yKxzGScm5jJUjOMjbiJLJcYw40IDUIrVj0vRxEAaxdFL-_CbbHo5T0ib5xkN791rNr-QNN-KQbdKhxjM9NCKp1YV-euOB5hrCy1K_bG6YhkQS-KIUDpAw-81eIfj38Z1KhA-3VFmbI2zdW6wAApd5Q8Kd79ca9Wm0UGDcXnbinc1i62z6DJeI7wwUSe_veVz8htt_4eFfec7HXtlXmB8VdX7fv3Fvve6n4DMikz7Q |
link.rule.ids | 230,315,733,786,790,870,891,2115,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtNAFB2VIgEb3tDwHCSWmcT2zNhjdiVQhdIUpIaqu5HnYZq2saPEAZUV_8Af8Sl8CXfGdtSUBYJNJHv8uskZ33sz556L0Eubp0kQ64A4qRDClImJ0Akn8EZUIs1iobxuwWg_Hn5iu0f8aAPxthbGk_a1mvSKs2mvmBx7buVsqvstT6z_cTRIQ5hnQdK_gq7CfI34hST9xK-tMQGBeVso59lc1hUausrzKOr59rSuZQ2F4AFSIr7mk7x0_5pr-jP0vMygvOCSdm6hw9aYmoly2ltWqqe_XdJ5_Gdrb6ObTZCKt-vhO2jDFnfRtVGzDH8P_TywMAMsPm6ajmAvA7XAOYCq_ArOEC_Op7Oq9HKwuOV7Fdj96YsPIJUmg_KQRPjD1NEBC5wVBr-xZ1WGv0Dq7pg5cBL2PT9sF0a0dW1LMHyt4a_vP3azAnB97jajV3gbz201L9uK0S6erVqSEeeiTRfDYwA0DXbNgOcV9oq699F45-14MCRNMwiiGU8rYvJcsEyFOg8oNzbmhmoL2WhqgsSEYWyUiBKrtDApszzQcS64gY9QBIrnlD5Am0VZ2C2ERaop41FObcKYDanIDIWwi9kgZwLCww4iLRrkrJb8kC0X7kTWQJLORFkDqYNeO8isjnWC3X5HOf8smx9SOjFoarjQJsrdErpisIfSLDNuHTmMOyhpASeb2KeOaeBSk7_c_kWLTwmvBrfekxW2XC4kxF6pU_uJ4eoPa7yuHrKFPtx3DclrVqyPAD69_HiDx0f_feZzdH04Hu3JvXf77x-jG86Wmnz3BG1W86V9CmFepZ75Sf0bALtU6w |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtNAFB1BkSo2vB8pr0FimUlsz9gesyspUSmkVGpBFZuR50XTNnaUOKCy4h_4Iz6FL-HO2I6SskDqxlL8vvEZ33t9z5yL0CtjszRIVECcVAhhUieEqzQm8EaUPMsTLr1uwWg_2f3E9o7j45VWX560r-S4V5xPesX4xHMrpxPVb3li_YPRIAthnAVpf6pt_zq6AWM2SlcS9VNfX2McgvN2spxndBk32dDNPo-inm9R69rWUAggIC2K1_ySl-9fc0__hp-XWZQrbml4G31pDarZKGe9RSV76sclrccrWXwH3WqCVbxd73IXXTPFPbQ5asrx99HvQwMjweCTpvkI9nJQc2wBXOV3cIp4fjGZVqWXhcUt76vA7uMvPoSUmgzKzyTCHyeOFljgvNB4x5xXOf4GKbxj6MBB2Pf-MF3YooxrX4Lhrw3__Py1lxeA7wv3M3qNt_HMVLOynTnaxdNlazLiXLXuYrgNgKjGrinwrMJeWfcBOhq-PRrskqYpBFEsziqireUsl6GyAY21SWJNlYGsNNNBqsMw0RLAYKTiOmMmDlRieaxhEfJAxpbSh2ijKAvzGGGeKcriyFKTMmZCynNNIfxiJrCMQ5jYQaRFhJjW0h-i5cSdihpMwpkoajB10BsHm-W-TrjbryhnX0XzMIUThaY65kpH1pXSJYM1lOa5dvXkMOmgtAWdaGKgOraBU43_c_mXLUYFvCJc3ScvTLmYC4jBMqf6k8DZH9WYXd5kC3-47hqa16xY3wIY9TLkDSa3rnzkC7R5sDMUH97tv3-CbjpTag7eU7RRzRbmGUR7lXzux_VfdeRXaw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Severe+hospital+events+following+symptomatic+infection+with+Sars-CoV-2+Omicron+and+Delta+variants+in+France%2C+December+2021%E2%80%93January+2022%3A+A+retrospective%2C+population-based%2C+matched+cohort+study&rft.jtitle=EClinicalMedicine&rft.au=Vincent+Auvigne&rft.au=Sophie+Vaux&rft.au=Yann+Le+Strat&rft.au=Justine+Schaeffer&rft.date=2022-06-01&rft.pub=Elsevier&rft.issn=2589-5370&rft.eissn=2589-5370&rft.volume=48&rft.spage=101455&rft_id=info:doi/10.1016%2Fj.eclinm.2022.101455&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_62753d58cd2f4466b462733aad503316 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2589-5370&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2589-5370&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2589-5370&client=summon |